文献速递临床微生物分子诊断质量管理与危急值

从「仅MIC」重回碳青霉烯酶检测:临床实验室需了解的CLSI更新要点

The shift from "MIC-Only" back to carbapenemase testing among carbapenem-resistant Enterobacterales: what clinical laboratories need to know about updated CLSI guidance.
PubMed 文献 · J Clin Microbiol · 2026-03-18

碳青霉烯耐药肠杆菌目(CRE)威胁全球健康,产碳青霉烯酶株尤其值得关注。2025年CLSI M100更新建议对至少对一种碳青霉烯耐药的肠杆菌目进行碳青霉烯酶检测,并区分KPC、NDM和OXA-48-like等关键酶以指导治疗和抗菌药物管理。本小型综述梳理了CLSI指南从建立折点到「仅MIC」时代再到当前耐药机制驱动框架的演变。

要点

  • 2025年CLSI M100建议对至少对一种碳青霉烯耐药的肠杆菌目进行碳青霉烯酶检测。
  • 检测应区分KPC、NDM和OXA-48-like等关键酶以指导治疗决策。
  • 需关注金属β-内酰胺酶与丝氨酸碳青霉烯酶共产时eCIM的修订。

核心结论

  • 碳青霉烯酶检测重新成为碳青霉烯耐药肠杆菌目临床实验室工作流程的重要部分,以支持治疗决策和抗菌药物管理。

研究设计与样本

  • 本文为小型综述,总结CLSI指南从早期折点建立、经历「仅MIC」时代到当前抗菌药物耐药机制驱动框架的演变。

主要发现

  • 碳青霉烯酶流行病学变化、酶特异性新型β-内酰胺联合药物的引入以及CLSI指南更新,共同提升了碳青霉烯酶检测在碳青霉烯耐药肠杆菌目中的重要性。
  • 2025年CLSI M100更新建议对至少对一种碳青霉烯耐药的多数肠杆菌目进行碳青霉烯酶检测,并强调区分KPC、NDM和OXA-48-like等关键酶。
  • 综述讨论了既往临床折点的局限性、不同场景下筛选标准灵敏度与特异性的平衡难题,以及快速表型和分子检测方法日益扩大的作用。
  • 本文结合金属β-内酰胺酶与丝氨酸碳青霉烯酶共产增加的情况,讨论了EDTA改良碳青霉烯灭活方法(eCIM)的修订。

临床怎么用

  • 临床微生物实验室应将碳青霉烯酶检测重新整合入临床工作流程,作为抗菌药物管理的关键组成部分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Carbapenem-resistant organisms (CROs) pose a major threat to global health due to limited therapeutic options and their capacity for rapid dissemination. Among these, carbapenemase-producing (CP) strains are of greatest concern, as they hydrolyze most β-lactams, and carbapenemase genes are readily spread via mobile genetic elements. Historically, clinical laboratories relied solely on minimal inhibitory concentration (MIC) results and interpretive criteria to guide therapy, with carbapenemase testing performed mainly for epidemiologic purposes. However, changing carbapenemase epidemiology, the introduction of enzyme-specific novel β-lactam combination agents for treatment, and updated Clinical and Laboratory Standards Institute (CLSI) guidance have renewed the importance of carbapenemase testing among carbapenem-resistant Enterobacterales. The 2025 CLSI M100 update now recommends carbapenemase testing for most Enterobacterales resistant to at least one carbapenem, emphasizing differentiation of key enzymes, such as KPC, NDM, and OXA-48-like, to inform therapeutic decisions and support antimicrobial stewardship. This minireview summarizes the evolution of CLSI guidance from early breakpoint establishment through the "MIC-only" era to the current antimicrobial resistance mechanism-driven framework. Key issues addressed include the clinical limitations of prior clinical breakpoints, challenges in balancing sensitivity and specificity of screening criteria to guide carbapenemase testing in different settings, and the expanding role of rapid phenotypic and molecular detection methods. Revisions to the EDTA-modified carbapenem inactivation method (eCIM) are discussed in light of increasing co-production of metallo-beta-lactamase and serine-carbapenemases. Reintegration of carbapenemase testing into clinical workflows highlights the role of the clinical microbiology laboratory as a critical component of antimicrobial stewardship.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Simner PJ. The shift from "MIC-Only" back to carbapenemase testing among carbapenem-resistant Enterobacterales: what clinical laboratories need to know about updated CLSI guidance. J Clin Microbiol. 2026. PMID: 41848331. doi:10.1128/jcm.00451-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。